Growth Hormone
Approved · EMAAlso known as Genotropin, Growth hormone (human), Human growth hormone, Humatrope+20 more
Genotropin, Growth hormone (human), Human growth hormone, Humatrope, Norditropin, Nutropin, Nutropin Depot, Omnitrope, SOMATROPIN, Saizen, Serostim, Somatotropin, Somatotropin (human), Somatotropin human, Somatotropin human growth hormone, Somatropina, Tev-tropin, Zomacton, Zorbtive, hGH, rhGH, Recombinant human growth hormone, Somatropin (Recombinant rhGH), Somatropin recombinant.
Recent clinical, regulatory, research and industry developments relating to this drug.
Low-dose Growth Hormone for the Treatment of Gastroparesis
Growth hormone treatment for neurologic symptoms of post-acute sequelae of COVID-19.
Recent insights into the role of hormones during development and their functional regulation.
A Superlong-Acting Growth Hormone-Polypeptide Fusion for Growth Hormone Deficiency Treatment.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Infants, children and adolescents Growth disturbance due to insufficient secretion of growth hormone (GH). Growth disturbance associated with Turner syndrome. Growth disturbance… Show full indicationShow less
Infants, children and adolescents Growth disturbance due to insufficient secretion of growth hormone (GH). Growth disturbance associated with Turner syndrome. Growth disturbance associated with chronic renal insufficiency. Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later. Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing. Adults Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.
Indication: Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. Long-term treatment of growth failure associated with Turner syndrome.… Show full indicationShow less
Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion. Long-term treatment of growth failure associated with Turner syndrome. Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The Journal of clinical endocrinology and metabolism6
- Frontiers in endocrinology4
- Endocrine journal2
- Hormone research in paediatrics2
- Advanced healthcare materials1
- Clinical and translational science1
- Yokoya S4
- de Muinck Keizer-Schrama SM3
- Drop SL3
- Gunnell L3
- Horikawa R3
- Klibanski A3
- Miller KK3
- Sas TC3
- Sophia Children's Hospital3
- Hamamatsu University School of Medicine2
- Massachusetts General Hospital and Harvard Medical School2
- National Center for Child Health and Development2
- Osaka University Graduate School of Medicine2
- Research Institute2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 7 of the same disease areas as Growth Hormone in the shared literature.
Studied across 6 of the same disease areas as Growth Hormone in the shared literature.
Studied across 6 of the same disease areas as Growth Hormone in the shared literature.
Studied across 6 of the same disease areas as Growth Hormone in the shared literature.
Studied across 5 of the same disease areas as Growth Hormone in the shared literature.
Studied across 3 of the same disease areas as Growth Hormone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.